Danaher Reports Second Quarter 2025 Results

Core Insights - Danaher Corporation reported strong second quarter results, driven by effective execution of the Danaher Business System and growth in the Bioprocessing segment [2][4] - The company anticipates continued growth in core sales and adjusted diluted net earnings for the remainder of 2025, despite a fluid macro environment [2][4] Financial Performance - For the second quarter of 2025, net earnings were $555 million, or $0.77 per diluted common share, with non-GAAP adjusted diluted net earnings per common share at $1.80 [9][12] - Revenues increased by 3.5% year-over-year to $5.9 billion, while non-GAAP core revenue grew by 1.5% [9][18] - Operating cash flow was reported at $1.3 billion, with non-GAAP free cash flow at $1.1 billion [9][20] Future Outlook - The company expects non-GAAP core revenue growth of low-single digits for the third quarter of 2025 and approximately 3% for the full year [4][18] - Adjusted diluted net earnings per common share guidance has been raised to a range of $7.70 to $7.80 for the full year, up from the previous range of $7.60 to $7.75 [4][18] Segment Performance - Total sales growth for the company was 3.5%, with the Biotechnology segment growing by 8.0%, while Life Sciences experienced a slight increase of 0.5% [18] - Core sales growth varied by segment, with Biotechnology at 6.0%, Life Sciences declining by 2.5%, and Diagnostics growing by 2.0% [18] Cash Flow and Investments - The net cash provided by operating activities was $1.338 billion, with total cash used in investing activities at $258 million [20] - Free cash flow for the quarter was reported at $1.094 billion, demonstrating the company's ability to generate cash after capital expenditures [20]